It's worth noting that the EMERALD trial of Radius/Menarini's elacestrant in HR-positive, HER2-negative breast cancer showed a 30% reduction in PFS, with most of the impact coming from a subgroup ...

Menarini/Stemline's Orserdu (elacestrant ... HER2-negative advanced breast cancer with ESR1 mutations. Meanwhile, AstraZeneca is vying to bring the first drug in the class to market as a first ...

Understanding how AI-driven bias affects Black patients and knowing how to advocate for equitable healthcare is essential.

Entering text into the input field will update the search result below Home page Seeking Alpha - Power to Investors Create free account ...

Entering text into the input field will update the search result below Home page Seeking Alpha - Power to Investors Create free account ...

Medical news, education and information for physicians and health care professionals, presented by specialty and topic. From Healio and the Wyanoke Group.